Tech Company Financing Transactions

Vico Therapeutics Funding Round

Ackermans & Van Haaren, Droia Ventures and EQT Life Sciences participated in a $60 million Series B funding round for Vico Therapeutics. The funding round was announced by the company on 1/5/2024.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

BioScience Park BioPartner Building 1 J.H. Oortweg 21
Leiden, 2333 CH
The Netherlands

Phone

+31 71 2036800

Website

www.vicotx.com

Email Address

[email protected]

Overview

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Our lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington's disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Micah Mackison

        

Chief Medical Officer

Scott Schobel

        

Chief Scientific Officer

Nicole Datson

        

Browse more venture capital transactions:

Prev: 1/5/2024: Komunal venture capital transaction
Next: 1/5/2024: Immunic Therapeutics venture capital transaction

Share this article

Where The Data Comes From

We report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary